Ashwin Desai founded Aether Industries at the age of 63, bringing to it a lifetime of experience in chemical engineering and a vision for building something genuinely different in the specialty chemicals space. He had studied chemical engineering at ICT Mumbai and spent decades working in the industry before deciding the time was right to build his own company. That late start, far from being a disadvantage, meant Aether was founded with exceptional clarity of purpose and technical depth.
Before Aether Industries was a company, it was an idea nurtured through years of patient preparation — notebooks, research, and a deep knowledge of where the specialty chemicals market had gaps that no Indian manufacturer was filling. Ashwin Desai spent years studying continuous flow chemistry and identifying molecules that global pharmaceutical and agrochemical companies needed but could not source reliably. The discipline of that preparation period is evident in every product Aether has launched since its founding in 2013.
Aether Industries was co-founded in 2013 by Ashwin Desai and his two sons — Rohan, who brought business and operations expertise, and Dr. Aman, who contributed advanced pharmaceutical research knowledge. The combination of Ashwin\'s industry experience, Rohan\'s commercial acumen, and Dr. Aman\'s scientific depth made for an unusually well-rounded founding team in a highly technical sector. Working as a family unit also gave Aether the long-term orientation essential in an industry where returns come only to those who invest consistently in science.
Aether Industries made continuous flow chemistry the cornerstone of its manufacturing model, achieving a level of precision, safety, and efficiency that conventional batch processes cannot match. The company became the number-one global producer of several specialty molecules, including 4-methylpiperidine and HEDA, supplying customers in pharmaceutical and agrochemical industries across 18 countries. This scientific leadership, developed by a team of over 200 researchers, is what sets Aether apart from every competitor in the Indian specialty chemicals industry.
Aether\'s manufacturing operations span three large facilities where more than 200 scientists and engineers develop and produce over 25 specialty chemical products to rigorous safety and quality standards. The company serves customers in pharmaceuticals, agrochemicals, and advanced materials sectors across Asia, Europe, and North America, with supply relationships built on years of consistent delivery. Investing in people, safety infrastructure, and process excellence from day one created an operational foundation that scaled without compromise as global demand grew.
In 2022, Aether Industries listed on the Indian stock exchanges in an IPO that was subscribed 6.26 times, reflecting strong conviction from institutional and retail investors in the company\'s business model and growth potential. The listing validated years of disciplined research investment and consistent customer delivery, converting scientific excellence into a market-recognised enterprise value. For a founder who started at 63, reaching a public listing in under a decade was a remarkable demonstration of what clarity of vision and deep technical capability can achieve.
Today, Aether Industries has a market capitalisation of approximately ₹10,000 crore and continues to grow its revenue at over 30% annually, making it one of India\'s fastest-growing specialty chemicals companies. Its state-of-the-art manufacturing facilities represent a world-class specialty chemicals ecosystem built from Surat, serving the most demanding global customers with products that require the highest levels of precision and purity. The Aether story proves that with the right expertise, the right timing, and the right team, a company built in any Indian city can compete and win on the world stage.